Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568275 | 0.72 | MAPK1 (0.44) | SMN1; SMN2ALDH1A1MAPK1POLBLMNA | |
| SCHEMBL22169259 | 0.72 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1MAPK1POLBLMNA | |
| SCHEMBL31336711 | 0.71 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1MAPK1POLBLMNA | |
| SCHEMBL1541111 | 0.69 | KDM4E (0.46) | ALDH1A1LMNAKDM4EMAPTTSHR | |
| SCHEMBL1795934 | 0.69 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MAPK1LMNARECQL | |
| SCHEMBL4909009 | 0.69 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1MAPK1LMNAMAPT | |
| SCHEMBL31518690 | 0.69 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1MAPK1KDM4EMAPT | |
| SCHEMBL25131969 | 0.69 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1MAPTTPMT | |
| SCHEMBL26841823 | 0.69 | KDM4E (0.37) | SMN1; SMN2ALDH1A1MAPK1POLBKDM4E | |
| SCHEMBL2373944 | 0.68 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1MAPK1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074808-B | Therapeutic compounds as orexin-1 receptor inhibitors | 希四克斯探索有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-2794593-B1 | SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2017-02-01 | — | — | EP | disclosed |
| US-9493438-B2 | 4,4-difluoro-piperidine-compounds | ROTTAPHARM S.R.L. (IT) | 2016-11-15 | — | — | US | disclosed |
| EP-2820007-B1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | Rottapharm Biotech Srl (IT) | 2016-04-20 | — | — | EP | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-20150051226-A1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | ROTTAPHARM S.P.A. (IT) | 2015-02-19 | — | — | US | disclosed |
| EP-2820007-A1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | Rottapharm Biotech S.r.l. (IT) | 2015-01-07 | — | — | EP | disclosed |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-12-04 | — | — | US | disclosed |
| EP-2794593-A1 | CHEMICAL COMPOUNDS | Rottapharm Biotech S.r.l. (IT) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013127913-A1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | ROTTAPHARM S.P.A. (IT) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013092893-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM SPA (IT) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051226-A1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | SLCO4C1, PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SMN1; SMN2 2505/4885ALDH1A1 1187/4885MAPK1 2728/4885 |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | HCRTR2, HCRTR1, NPY1R | SMN1; SMN2 2688/4885ALDH1A1 1588/4885MAPK1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.